×
S&P 500   3,839.75 (+0.22%)
DOW   30,992.99 (+0.08%)
QQQ   290.18 (+1.12%)
AAPL   143.82 (+1.60%)
MSFT   267.33 (+1.70%)
META   170.58 (+1.42%)
GOOGL   2,304.29 (+1.72%)
AMZN   114.86 (+1.20%)
TSLA   697.69 (-0.22%)
NVDA   152.33 (+1.80%)
NIO   20.84 (-6.04%)
BABA   119.84 (-0.24%)
AMD   75.91 (+0.94%)
MU   57.70 (+1.71%)
CGC   2.68 (-1.11%)
T   21.18 (+0.05%)
GE   61.83 (-0.32%)
F   11.16 (-0.36%)
DIS   96.68 (-0.51%)
AMC   12.60 (-1.41%)
PFE   52.90 (+2.44%)
PYPL   73.73 (-0.90%)
NFLX   185.18 (-0.38%)
S&P 500   3,839.75 (+0.22%)
DOW   30,992.99 (+0.08%)
QQQ   290.18 (+1.12%)
AAPL   143.82 (+1.60%)
MSFT   267.33 (+1.70%)
META   170.58 (+1.42%)
GOOGL   2,304.29 (+1.72%)
AMZN   114.86 (+1.20%)
TSLA   697.69 (-0.22%)
NVDA   152.33 (+1.80%)
NIO   20.84 (-6.04%)
BABA   119.84 (-0.24%)
AMD   75.91 (+0.94%)
MU   57.70 (+1.71%)
CGC   2.68 (-1.11%)
T   21.18 (+0.05%)
GE   61.83 (-0.32%)
F   11.16 (-0.36%)
DIS   96.68 (-0.51%)
AMC   12.60 (-1.41%)
PFE   52.90 (+2.44%)
PYPL   73.73 (-0.90%)
NFLX   185.18 (-0.38%)
S&P 500   3,839.75 (+0.22%)
DOW   30,992.99 (+0.08%)
QQQ   290.18 (+1.12%)
AAPL   143.82 (+1.60%)
MSFT   267.33 (+1.70%)
META   170.58 (+1.42%)
GOOGL   2,304.29 (+1.72%)
AMZN   114.86 (+1.20%)
TSLA   697.69 (-0.22%)
NVDA   152.33 (+1.80%)
NIO   20.84 (-6.04%)
BABA   119.84 (-0.24%)
AMD   75.91 (+0.94%)
MU   57.70 (+1.71%)
CGC   2.68 (-1.11%)
T   21.18 (+0.05%)
GE   61.83 (-0.32%)
F   11.16 (-0.36%)
DIS   96.68 (-0.51%)
AMC   12.60 (-1.41%)
PFE   52.90 (+2.44%)
PYPL   73.73 (-0.90%)
NFLX   185.18 (-0.38%)
S&P 500   3,839.75 (+0.22%)
DOW   30,992.99 (+0.08%)
QQQ   290.18 (+1.12%)
AAPL   143.82 (+1.60%)
MSFT   267.33 (+1.70%)
META   170.58 (+1.42%)
GOOGL   2,304.29 (+1.72%)
AMZN   114.86 (+1.20%)
TSLA   697.69 (-0.22%)
NVDA   152.33 (+1.80%)
NIO   20.84 (-6.04%)
BABA   119.84 (-0.24%)
AMD   75.91 (+0.94%)
MU   57.70 (+1.71%)
CGC   2.68 (-1.11%)
T   21.18 (+0.05%)
GE   61.83 (-0.32%)
F   11.16 (-0.36%)
DIS   96.68 (-0.51%)
AMC   12.60 (-1.41%)
PFE   52.90 (+2.44%)
PYPL   73.73 (-0.90%)
NFLX   185.18 (-0.38%)
NASDAQ:PALI

Palisade Bio Stock Forecast, Price & News

$0.42
+0.03 (+6.44%)
(As of 07/5/2022 05:46 PM ET)
Add
Compare
Today's Range
$0.38
$0.44
50-Day Range
$0.40
$0.80
52-Week Range
$0.37
$4.33
Volume
159,767 shs
Average Volume
169,392 shs
Market Capitalization
$9.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Palisade Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,313.1% Upside
$6.00 Price Target
Short Interest
Healthy
2.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.78mentions of Palisade Bio in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.57) to ($0.29) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.00 out of 5 stars

30 days | 90 days | 365 days | Advanced Chart

Receive PALI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Palisade Bio and its competitors with MarketBeat's FREE daily newsletter.

About Palisade Bio

Palisade Bio, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress caused by reduced blood flow to the intestine, infections, and surgery. The company was founded in 2005 and is based in Carlsbad, California.

PALI Stock News Headlines

Palisade Bio (NASDAQ:PALI) Stock Price Down 2.3%
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
1 Stock With Growth Potential
This could be one of the best stocks to consider during this bear market run.
Palisade Bio to raise $2M in stock offering
Palisade Bio files for $100M mixed shelf offering
Palisade Drops on Results
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PALI
Fax
N/A
Employees
13
Year Founded
N/A

Company Calendar

Last Earnings
5/13/2022
Today
7/06/2022
Next Earnings (Estimated)
8/23/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+1,313.1%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
2 Analysts

Profitability

Net Income
$-26,620,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10,000.00
Book Value
$0.52 per share

Miscellaneous

Free Float
16,333,000
Market Cap
$9.29 million
Optionable
Not Optionable
Beta
1.66














Palisade Bio Frequently Asked Questions

Should I buy or sell Palisade Bio stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palisade Bio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Palisade Bio stock.
View analyst ratings for Palisade Bio
or view top-rated stocks.

What is Palisade Bio's stock price forecast for 2022?

2 brokers have issued 1 year price targets for Palisade Bio's shares. Their PALI stock forecasts range from $5.00 to $7.00. On average, they expect Palisade Bio's share price to reach $6.00 in the next year. This suggests a possible upside of 1,313.1% from the stock's current price.
View analysts' price targets for Palisade Bio
or view top-rated stocks among Wall Street analysts.

How has Palisade Bio's stock price performed in 2022?

Palisade Bio's stock was trading at $1.30 at the start of the year. Since then, PALI stock has decreased by 67.3% and is now trading at $0.4246.
View the best growth stocks for 2022 here
.

When is Palisade Bio's next earnings date?

Palisade Bio is scheduled to release its next quarterly earnings announcement on Tuesday, August 23rd 2022.
View our earnings forecast for Palisade Bio
.

How were Palisade Bio's earnings last quarter?

Palisade Bio, Inc. (NASDAQ:PALI) announced its quarterly earnings results on Friday, May, 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.02.
View Palisade Bio's earnings history
.

Who are Palisade Bio's key executives?

Palisade Bio's management team includes the following people:
  • Dr. Thomas M. Hallam Ph.D., CEO & Director (Age 47, Pay $644.39k)
  • Mr. J. D. Finley, Chief Financial Officer (Age 64, Pay $519.39k)
  • Dr. Michael John Dawson M.D., Chief Medical Officer (Age 53, Pay $139.55k)
  • Mr. John J. Rodenrys, Co-Founder, EVP & CTO (Age 78)
  • Ms. Sharon McBrayer, Director of Operations
  • Mr. Robert C. McRae, Sr. VP of Operations & Strategic Devel.

What is Palisade Bio's stock symbol?

Palisade Bio trades on the NASDAQ under the ticker symbol "PALI."

How do I buy shares of Palisade Bio?

Shares of PALI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Palisade Bio's stock price today?

One share of PALI stock can currently be purchased for approximately $0.42.

How much money does Palisade Bio make?

Palisade Bio (NASDAQ:PALI) has a market capitalization of $9.29 million and generates $10,000.00 in revenue each year. The company earns $-26,620,000.00 in net income (profit) each year or ($3.20) on an earnings per share basis.

How many employees does Palisade Bio have?

Palisade Bio employs 13 workers across the globe.

How can I contact Palisade Bio?

Palisade Bio's mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The official website for Palisade Bio is leadingbiosciences.com. The company can be reached via phone at (858) 704-4900 or via email at investor@senecabio.com.

This page (NASDAQ:PALI) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.